Kristien Boelaert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kristien Boelaert has a total of 426 co-authors. Here are the top co-authors by number of shared publications:
- Martin L. Read
University of Birmingham
45 shared publications - Vicki E. Smith
University of Birmingham
40 shared publications - Hannah R. Nieto
Institute of Metabolism and Systems Research University of Birmingham Birmingham UK
36 shared publications - Caroline M. Gorvin
University of Birmingham
35 shared publications - Christopher J. McCabe
Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, UK
35 shared publications - Jana Kim
School of Biomedical Engineering & Imaging Sciences, King’s College London, St Thomas’ Hospital, London SE1 7EH, U.K.
35 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Iopanoic acid in severe thyrotoxicosis: rediscovering an effective therapy
Background: Severe thyrotoxicosis remains a high-risk endocrine emergency, particularly in thyroid storm and amiodarone-induced thyrotoxicosis (AIT), where morbidity and mortality remain substantial despite modern intensive care. Rapid reduction of circulating triiodothyronine (T3) is central to stabilization, yet conventional therapies are often slow, unpredictable, or ineffective, particularly in iodine-replete states such as AIT. Summary: We reviewed mechanistic, pharmacokinetic, and clinical evidence for iopanoic acid, a potent inhibitor of type I and type II 5′-deiodinase that produces rapid, reversible suppression of peripheral thyroxine (T4) to T3 conversion, alongside comparative rescue strategies including Lugol iodine, perchlorate, lithium, cholestyramine, and therapeutic plasma exchange. Across early clinical studies and a contemporary tertiary-center case series, short-course iopanoic acid consistently produced large, rapid reductions in serum T3, typically within 24 to 48 hours, with parallel clinical improvement. In a recent series of 12 patients with treatment-resistant thyrotoxicosis, mean free T3 fell by approximately 55%, normalizing within a median of 2 days and enabling progression to definitive surgery in most cases. Reported use extends beyond thyroid storm to urgent preoperative preparation of uncontrolled hyperthyroidism, AIT, and destructive thyroiditis. Adverse effects are uncommon and generally mild, and withdrawal from routine clinical use reflects the obsolescence of oral cholecystography rather than safety concerns. Conclusion: Iopanoic acid offers safe, rapid, and predictable T3 reduction as short-course rescue or bridging therapy in thyroid storm and refractory, iodine-unresponsive AIT, where it can be lifesaving. It is not recommended for straightforward thyrotoxicosis. We synthesize the evidence into a pragmatic, protocol-based framework and argue that reliable, appropriately governed sourcing is now the principal barrier to its use.
- 14 October 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Open AccessIopanoic acid in severe thyrotoxicosis: rediscovering an effective therapy
Background: Severe thyrotoxicosis remains a high-risk endocrine emergency, particularly in thyroid storm and amiodarone-induced thyrotoxicosis (AIT), where morbidity and mortality remain substantial despite modern intensive care. Rapid reduction of circulating triiodothyronine (T3) is central to stabilization, yet conventional therapies are often slow, unpredictable, or ineffective, particularly in iodine-replete states such as AIT. Summary: We reviewed mechanistic, pharmacokinetic, and clinical evidence for iopanoic acid, a potent inhibitor of type I and type II 5′-deiodinase that produces rapid, reversible suppression of peripheral thyroxine (T4) to T3 conversion, alongside comparative rescue strategies including Lugol iodine, perchlorate, lithium, cholestyramine, and therapeutic plasma exchange. Across early clinical studies and a contemporary tertiary-center case series, short-course iopanoic acid consistently produced large, rapid reductions in serum T3, typically within 24 to 48 hours, with parallel clinical improvement. In a recent series of 12 patients with treatment-resistant thyrotoxicosis, mean free T3 fell by approximately 55%, normalizing within a median of 2 days and enabling progression to definitive surgery in most cases. Reported use extends beyond thyroid storm to urgent preoperative preparation of uncontrolled hyperthyroidism, AIT, and destructive thyroiditis. Adverse effects are uncommon and generally mild, and withdrawal from routine clinical use reflects the obsolescence of oral cholecystography rather than safety concerns. Conclusion: Iopanoic acid offers safe, rapid, and predictable T3 reduction as short-course rescue or bridging therapy in thyroid storm and refractory, iodine-unresponsive AIT, where it can be lifesaving. It is not recommended for straightforward thyrotoxicosis. We synthesize the evidence into a pragmatic, protocol-based framework and argue that reliable, appropriately governed sourcing is now the principal barrier to its use.
- Open Access
- 21 May 2026
- Published by IOS Press
- Vol. 336, 670-674
A Hybrid Delphi-Inspired Expert–LLM Workflow for Efficient Evidence Screening in Systematic Reviews
Systematic reviews are essential for evidence-based healthcare but remain highly resource-intensive, with most retrieved studies ultimately excluded after manual screening. This study developed and evaluated a hybrid expert–LLM workflow to reduce human workload while maintaining accuracy and transparency. Within the Thyroid Risk Stratification Tool (ThyRST) project, ChatGPT-5 was used to classify 14,858 records on thyroid nodule malignancy risk into thematic categories. Recurrent irrelevant concepts were refined through expert consensus involving clinicians and informaticians and embedded as exclusion rules in structured prompts. The model then labelled each abstract as INCLUDE, EXCLUDE, or MAYBE, producing outputs for audit and verification. A random sample of 100 records was independently reviewed by human assessors to evaluate performance. The workflow achieved 96% concordance (κ = 0.91) with human reviewers, with only one false exclusion, and reduced manual screening time by approximately 70%. These results demonstrate that a transparent Delphi-inspired expert–LLM can accurately and reproducibly automate early-stage evidence screening, providing substantial efficiency gains while preserving human oversight and methodological rigor. The approach offers a practical pathway toward the responsible integration of generative AI in systematic review methodology and digital health research.
- 21 May 2026
- Published by IOS Press
- Vol. 336, 670-674
Open AccessA Hybrid Delphi-Inspired Expert–LLM Workflow for Efficient Evidence Screening in Systematic Reviews
Systematic reviews are essential for evidence-based healthcare but remain highly resource-intensive, with most retrieved studies ultimately excluded after manual screening. This study developed and evaluated a hybrid expert–LLM workflow to reduce human workload while maintaining accuracy and transparency. Within the Thyroid Risk Stratification Tool (ThyRST) project, ChatGPT-5 was used to classify 14,858 records on thyroid nodule malignancy risk into thematic categories. Recurrent irrelevant concepts were refined through expert consensus involving clinicians and informaticians and embedded as exclusion rules in structured prompts. The model then labelled each abstract as INCLUDE, EXCLUDE, or MAYBE, producing outputs for audit and verification. A random sample of 100 records was independently reviewed by human assessors to evaluate performance. The workflow achieved 96% concordance (κ = 0.91) with human reviewers, with only one false exclusion, and reduced manual screening time by approximately 70%. These results demonstrate that a transparent Delphi-inspired expert–LLM can accurately and reproducibly automate early-stage evidence screening, providing substantial efficiency gains while preserving human oversight and methodological rigor. The approach offers a practical pathway toward the responsible integration of generative AI in systematic review methodology and digital health research.
- Open Access
- 17 May 2026
- Published by Wiley in Clinical Endocrinology
What Endocrinologists Should Know About Iodine: Population Deficiency, Individual Excess and Misinformation in the United Kingdom
Iodine deficiency, once considered eliminated in the United Kingdom, has re‐emerged, particularly among women of reproductive age, in whom requirements are increased during pregnancy and lactation. The declining consumption of dairy and white fish, the emerging use of unfortified plant‐based milk alternatives, and the absence of a national iodisation policy have contributed to a return of mild to moderate iodine deficiency. Vegans and individuals avoiding dairy are at particular risk. Simultaneously, social‐media‐driven wellness trends promote ‘thyroid detoxes’ or ‘iodine resets’ and kelp‐based supplements that deliver supraphysiological iodine doses far exceeding recommended intake. Endocrinologists now face a dual challenge: widespread under‐recognition of population iodine insufficiency and a growing minority of patients presenting with iodine‐induced thyroid dysfunction. This review summarises current UK iodine status, the physiological and clinical relevance of iodine to thyroid and neurodevelopmental health, modern dietary risk factors and the clinical approach to those influenced by online misinformation. Routine dietary counselling and public health fortification represent cost‐effective interventions to prevent both extremes. Population‐based solutions would correct iodine status efficiently and align the UK with other high‐income countries.
- 17 May 2026
- Published by Wiley in Clinical Endocrinology
Open AccessWhat Endocrinologists Should Know About Iodine: Population Deficiency, Individual Excess and Misinformation in the United Kingdom
Iodine deficiency, once considered eliminated in the United Kingdom, has re‐emerged, particularly among women of reproductive age, in whom requirements are increased during pregnancy and lactation. The declining consumption of dairy and white fish, the emerging use of unfortified plant‐based milk alternatives, and the absence of a national iodisation policy have contributed to a return of mild to moderate iodine deficiency. Vegans and individuals avoiding dairy are at particular risk. Simultaneously, social‐media‐driven wellness trends promote ‘thyroid detoxes’ or ‘iodine resets’ and kelp‐based supplements that deliver supraphysiological iodine doses far exceeding recommended intake. Endocrinologists now face a dual challenge: widespread under‐recognition of population iodine insufficiency and a growing minority of patients presenting with iodine‐induced thyroid dysfunction. This review summarises current UK iodine status, the physiological and clinical relevance of iodine to thyroid and neurodevelopmental health, modern dietary risk factors and the clinical approach to those influenced by online misinformation. Routine dietary counselling and public health fortification represent cost‐effective interventions to prevent both extremes. Population‐based solutions would correct iodine status efficiently and align the UK with other high‐income countries.
- 17 March 2026
- Published by SAGE Publications in Obstetric Medicine
- Vol. 19 (2) , 155-157
A response to concerns regarding the green-top guideline on the “Management of thyroid disorders in pregnancy”
- 17 March 2026
- Published by SAGE Publications in Obstetric Medicine
- Vol. 19 (2) , 155-157
A response to concerns regarding the green-top guideline on the “Management of thyroid disorders in pregnancy”
- Open Access
- 5 March 2026
- Published by Wiley in Clinical Endocrinology
- Vol. 104 (6) , 682-692
Evaluation and Management of Thyroid Nodules: A Joint Consensus Statement From the British Thyroid Association (BTA), British Association of Endocrine and Thyroid Surgeons (BAETS) and Collaborating Bodies
- 5 March 2026
- Published by Wiley in Clinical Endocrinology
- Vol. 104 (6) , 682-692
Open AccessEvaluation and Management of Thyroid Nodules: A Joint Consensus Statement From the British Thyroid Association (BTA), British Association of Endocrine and Thyroid Surgeons (BAETS) and Collaborating Bodies
- Open Access
- 9 January 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (4) , 911-921
Thyrotoxicosis in MCT8 deficiency
Monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan–Herndon–Dudley syndrome, is a rare, severely debilitating, and life-limiting genetic disorder caused by variants in the SLC16A2 gene that render the MCT8 thyroid hormone transporter partially or completely dysfunctional. MCT8 is highly expressed throughout the body, including the brain. Its deficiency disrupts thyroid hormone homeostasis and is associated with 2 distinct concomitant clinical presentations: persistent peripheral thyrotoxicosis resulting from elevated serum levels of triiodothyronine and neurodevelopmental impairment arising from low thyroid hormone levels in the brain. The disorder severely impacts quality of life and reduces life expectancy to a median of 35 years due to a range of clinical sequelae, with approximately 30% of affected individuals dying during childhood. Recognition and treatment of thyrotoxicosis are crucial to prevent associated symptoms and long-term sequelae.
- 9 January 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (4) , 911-921
Open AccessThyrotoxicosis in MCT8 deficiency
Monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan–Herndon–Dudley syndrome, is a rare, severely debilitating, and life-limiting genetic disorder caused by variants in the SLC16A2 gene that render the MCT8 thyroid hormone transporter partially or completely dysfunctional. MCT8 is highly expressed throughout the body, including the brain. Its deficiency disrupts thyroid hormone homeostasis and is associated with 2 distinct concomitant clinical presentations: persistent peripheral thyrotoxicosis resulting from elevated serum levels of triiodothyronine and neurodevelopmental impairment arising from low thyroid hormone levels in the brain. The disorder severely impacts quality of life and reduces life expectancy to a median of 35 years due to a range of clinical sequelae, with approximately 30% of affected individuals dying during childhood. Recognition and treatment of thyrotoxicosis are crucial to prevent associated symptoms and long-term sequelae.
- Open Access
- 21 December 2025
- Published by Wiley in Clinical Endocrinology
- Vol. 104 (5) , 507-509
Joint Society Statement From the Society for Endocrinology (SfE), the British Thyroid Association (BTA) and the British Association of Endocrine and Thyroid Surgeons (BAETS) Regarding the Association of GLP‐1 Agonists and Thyroid Cancer
- 21 December 2025
- Published by Wiley in Clinical Endocrinology
- Vol. 104 (5) , 507-509
Open AccessJoint Society Statement From the Society for Endocrinology (SfE), the British Thyroid Association (BTA) and the British Association of Endocrine and Thyroid Surgeons (BAETS) Regarding the Association of GLP‐1 Agonists and Thyroid Cancer
- Open Access
- 3 December 2025
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (1)
An Unusual Presentation of Severe Hypothyroidism in a Child With Undiagnosed Systemic Lupus Erythematous
Myxedema is increasingly rare in the United Kingdom, particularly among patients already on treatment. We present a case of a 13-year-old girl diagnosed with autoimmune hypothyroidism who was started on 75 µg of levothyroxine by her general practitioner. She was referred to the endocrine clinic after 6 months of treatment for hypothyroidism with 2 months of worsening fatigue, chest pain, peripheral edema, and dyspnea. On hospitalization, the patient’s laboratory tests revealed undetectable free thyroxine level (fT4) and elevated thyrotropin (TSH) greater than 500 μIU/mL (SI: >500 m mIU/L) (reference range, 0.51-4.30 μIU/mL [SI: 0.51-4.30 mIU/L]). She was diagnosed with thyroid myxedema and commenced intravenous (IV) hydrocortisone, IV maintenance fluids, and antibiotics. However, the constellation of signs and symptoms remained perplexing. Further tests revealed a large pericardial effusion, deep vein thrombosis, and nephritis. A multidisciplinary approach confirmed the diagnosis of systemic lupus erythematous (SLE), and the patient was successfully started on rituximab therapy within 5 days of admission. This case illustrates the importance of considering potential underlying diagnoses when assessing patients with hypothyroid crisis, especially when symptoms deviate from the typical clinical presentation. The timely recognition and management of this patient's underlying SLE were crucial in her recovery.
- 3 December 2025
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (1)
Open AccessAn Unusual Presentation of Severe Hypothyroidism in a Child With Undiagnosed Systemic Lupus Erythematous
Myxedema is increasingly rare in the United Kingdom, particularly among patients already on treatment. We present a case of a 13-year-old girl diagnosed with autoimmune hypothyroidism who was started on 75 µg of levothyroxine by her general practitioner. She was referred to the endocrine clinic after 6 months of treatment for hypothyroidism with 2 months of worsening fatigue, chest pain, peripheral edema, and dyspnea. On hospitalization, the patient’s laboratory tests revealed undetectable free thyroxine level (fT4) and elevated thyrotropin (TSH) greater than 500 μIU/mL (SI: >500 m mIU/L) (reference range, 0.51-4.30 μIU/mL [SI: 0.51-4.30 mIU/L]). She was diagnosed with thyroid myxedema and commenced intravenous (IV) hydrocortisone, IV maintenance fluids, and antibiotics. However, the constellation of signs and symptoms remained perplexing. Further tests revealed a large pericardial effusion, deep vein thrombosis, and nephritis. A multidisciplinary approach confirmed the diagnosis of systemic lupus erythematous (SLE), and the patient was successfully started on rituximab therapy within 5 days of admission. This case illustrates the importance of considering potential underlying diagnoses when assessing patients with hypothyroid crisis, especially when symptoms deviate from the typical clinical presentation. The timely recognition and management of this patient's underlying SLE were crucial in her recovery.
- Open Access
- 28 November 2025
- Published by Bioscientifica in European Thyroid Journal
- Vol. 14 (6)
Comparing the diagnostic accuracy of Afirma GSC to ThyroSeq V3 in cytologically indeterminate thyroid nodules
Objective: To compare the diagnostic test accuracy of Afirma GSC and ThyroSeq v3 in cytologically indeterminate thyroid nodules. Methods: PubMed, Embase, Cochrane Library, Medline, and the Web of Science were searched from the date of inception to May 9, 2025. Two independent reviewers screened articles for eligibility. Studies assessing Afirma gene sequencing classifier (GSC) or ThyroSeq v3 for indeterminate thyroid nodules were included. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis reporting guidelines were followed. Statistical analysis was performed using R. Results: A total of 26 studies met the eligibility criteria. For surgically confirmed Afirma GSC results, the sensitivity, specificity, and negative predictive value (NPV) were 94, 42, and 96%, respectively. For unoperated negative cases, the values were 96, 86, and 99%. For ThyroSeq v3, the sensitivity, specificity, and NPV for surgically confirmed cases were 96, 40, and 93%, respectively, and for unoperated negative cases, they were 97, 83, and 99%. Conclusion: Both molecular tests demonstrate high NPV but low specificity; neither is clearly superior. Future research should prioritise randomised controlled trials, long-term follow-up of unoperated nodules, and direct comparisons of molecular tests.
- 28 November 2025
- Published by Bioscientifica in European Thyroid Journal
- Vol. 14 (6)
Open AccessComparing the diagnostic accuracy of Afirma GSC to ThyroSeq V3 in cytologically indeterminate thyroid nodules
Objective: To compare the diagnostic test accuracy of Afirma GSC and ThyroSeq v3 in cytologically indeterminate thyroid nodules. Methods: PubMed, Embase, Cochrane Library, Medline, and the Web of Science were searched from the date of inception to May 9, 2025. Two independent reviewers screened articles for eligibility. Studies assessing Afirma gene sequencing classifier (GSC) or ThyroSeq v3 for indeterminate thyroid nodules were included. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis reporting guidelines were followed. Statistical analysis was performed using R. Results: A total of 26 studies met the eligibility criteria. For surgically confirmed Afirma GSC results, the sensitivity, specificity, and negative predictive value (NPV) were 94, 42, and 96%, respectively. For unoperated negative cases, the values were 96, 86, and 99%. For ThyroSeq v3, the sensitivity, specificity, and NPV for surgically confirmed cases were 96, 40, and 93%, respectively, and for unoperated negative cases, they were 97, 83, and 99%. Conclusion: Both molecular tests demonstrate high NPV but low specificity; neither is clearly superior. Future research should prioritise randomised controlled trials, long-term follow-up of unoperated nodules, and direct comparisons of molecular tests.
- Open Access
- 26 June 2025
- Published by IOS Press
- Vol. 328, 56-60
Enhancing Diagnostic Precision: Utilising a Large Language Model to Extract U Scores from Thyroid Sonography Reports
This study evaluates the performance of ChatGPT-4, a Large Language Model (LLM), in automatically extracting U scores from free-text thyroid ultrasound reports collected from University Hospitals Birmingham (UHB), UK, between 2014 and 2024. The LLM was provided with guidelines on the U classification system and extracted U scores independently from 14,248 de-identified reports, without access to human-assigned scores. The LLM-extracted scores were compared to initial clinician-assigned and refined U scores provided by expert reviewers. The LLM achieved 97.7% agreement with refined human U scores, successfully identifying the highest U score in 98.1% of reports with multiple nodules. Most discrepancies (2.5%) were linked to ambiguous descriptions, multi-nodule reports, and cases with human-documented uncertainty. While the results demonstrate the potential for LLMs to improve reporting consistency and reduce manual workload, ethical and governance challenges such as transparency, privacy, and bias must be addressed before routine clinical deployment. Embedding LLMs into reporting workflows, such as Online Analytical Processing (OLAP) tools, could further enhance reporting quality and consistency.
- 26 June 2025
- Published by IOS Press
- Vol. 328, 56-60
Open AccessEnhancing Diagnostic Precision: Utilising a Large Language Model to Extract U Scores from Thyroid Sonography Reports
This study evaluates the performance of ChatGPT-4, a Large Language Model (LLM), in automatically extracting U scores from free-text thyroid ultrasound reports collected from University Hospitals Birmingham (UHB), UK, between 2014 and 2024. The LLM was provided with guidelines on the U classification system and extracted U scores independently from 14,248 de-identified reports, without access to human-assigned scores. The LLM-extracted scores were compared to initial clinician-assigned and refined U scores provided by expert reviewers. The LLM achieved 97.7% agreement with refined human U scores, successfully identifying the highest U score in 98.1% of reports with multiple nodules. Most discrepancies (2.5%) were linked to ambiguous descriptions, multi-nodule reports, and cases with human-documented uncertainty. While the results demonstrate the potential for LLMs to improve reporting consistency and reduce manual workload, ethical and governance challenges such as transparency, privacy, and bias must be addressed before routine clinical deployment. Embedding LLMs into reporting workflows, such as Online Analytical Processing (OLAP) tools, could further enhance reporting quality and consistency.